Compare WSC & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSC | IDYA |
|---|---|---|
| Founded | 1944 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.9B |
| IPO Year | 2015 | 2019 |
| Metric | WSC | IDYA |
|---|---|---|
| Price | $18.94 | $31.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $24.14 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.8M | 1.4M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,281,446,000.00 | $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.54 | $199.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $14.91 | $16.07 |
| 52 Week High | $31.88 | $39.28 |
| Indicator | WSC | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.59 | 48.87 |
| Support Level | $18.49 | $29.29 |
| Resistance Level | $19.63 | $34.76 |
| Average True Range (ATR) | 0.81 | 2.15 |
| MACD | 0.28 | 0.06 |
| Stochastic Oscillator | 78.78 | 23.95 |
WillScot Holdings Corp designs, delivers, and services on-site, on-demand space solutions for clients. The company offers turnkey solutions in construction, education, manufacturing, retail, healthcare, and entertainment sectors. The products of the company include modular office complexes, mobile offices, classrooms, blast-resistant modules, clearspan structures, sanitation solutions, portable storage containers, and climate-controlled containers and trailers.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.